Hôpital Lariboisière Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2018
NCT03395223
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

APHP-Hôpital Lariboisière | Hôpital Lariboisière | Hôpital Lariboisière APHP | Hôpital Lariboisière Fernand Widal | Hôpitaux Universitaires Saint-Louis-Lariboisière | Lariboisière Hospital -physical medicine and rehabilitation department | Lariboisière-Saint Louis clinical research unit

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

CADASIL (Phase 2)

Dementia, Multi-Infarct (Phase 2)

Methemoglobinemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 12